Pharmaron tallies repurchases of two series of convertibles due 2026

By Mary-Katherine Stinson

Lexington, Ky., Jan. 12 – Pharmaron Beijing Co. Ltd. announced repurchases of its $300 million 0% series 1 convertible bonds due 2026 and RMB 1.916 billion 0% dollar-settled series 2 convertible bonds due 2026, according to multiple notices.

Between Jan. 8 and Jan. 12, the company repurchased $68.1 million principal amount of the series 1 bonds, representing 22.7% of the original issue. The bonds had the rights to convert into 4,789,469 company shares.

Durning the same period, Pharmaron bought back RMB 705 million of the series 2 bonds, representing 36.8% of the original issue. The bonds had the rights to convert into 8,478,572 company shares.

The repurchased bonds will be canceled as soon as possible, leaving $231.9 million of the series 1 bonds and RMB 1.211 billion of the series 2 bonds outstanding.

Citicorp International Ltd. is the trustee.

Pharmaron is a Beijing-based research and development service provider for the life sciences industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.